Review article: Evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1033-1042

  Dupont, H L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; DOXYCYCLINE; GALACTOSE OLIGOSACCHARIDE; GLUTAMINE; NEOMYCIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG; XYLOOLIGOSACCHARIDE;

ABDOMINAL PAIN; COLON MOTILITY; CONSTIPATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; FLATULENCE; HUMAN; HYPERSENSITIVITY; INTESTINE FLORA; IRRITABLE COLON; MUCOSA INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH DISTENSION; VISCERAL HYPERSENSITIVITY;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MICROBIOTA; MOLECULAR TARGETED THERAPY; PROBIOTICS;

EID: 84899074874     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12728     Document Type: Review

References (92)

1. Dean BB, Aguilar D, Barghout V, et al,. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005; 11: S17-26.
2. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA,. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
3. Bolino CM, Bercik P,. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am 2010; 24: 961-75, ix.
4. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R,. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006; 24: 21-37.
5. Ford AC, Talley NJ,. Irritable bowel syndrome. BMJ 2012; 345: e5836.
6. Lovell RM, Ford AC,. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
7. Ringel Y, Carroll IM,. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009; 19: 141-50, vii.
8. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW,. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; 10: CD003460.
9. Olden KW,. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 2012; 5: 69-100.
10. Ohman L, Simren M,. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013; 15: 323.
11. Berg RD,. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430-5.
12. Marchesi J, Shanahan F,. The normal intestinal microbiota. Curr Opin Infect Dis 2007; 20: 508-13.
13. Carroll IM, Ringel-Kulka T, Keku TO, et al,. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 301: G799-807.
14. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y,. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: e248.
15. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al,. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
16. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR,. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55: 392-7.
17. Halvorson HA, Schlett CD, Riddle MS,. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 2006; 101: 1894-9.
18. Ford AC, Spiegel BM, Talley NJ, Moayyedi P,. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-86.
19. Simrén M, Barbara G, Flint HJ, et al,. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-76.
20. Borody TJ, George L, Andrews P, et al,. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150: 604.
21. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A,. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44: 551-61.
22. Ortiz-Lucas M, Tobias A, Saz P, Sebastián JJ,. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Rev Esp Enferm Dig 2013; 105: 19-36.
23. Sachdev AH, Pimentel M,. Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 2012; 14: 439-45.
24. Pimentel M, Chang C,. Inflammation and microflora. Gastroenterol Clin North Am 2011; 40: 69-85.
25. Chassard C, Dapoigny M, Scott KP, et al,. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-38.
26. Durban A, Abellan JJ, Jimenez-Hernandez N, et al,. Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep 2012; 4: 242-7.
27. Durban A, Abellan JJ, Jimenez-Hernandez N, et al,. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol 2013; 86: 581-9.
28. Ng SC, Lam EF, Lam TT, et al,. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol 2013; 28: 1624-31.
29. Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al,. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2013; doi: 10.1136/gutjnl-2013- 305994 [Epub ahead of print].
30. Parkes GC, Rayment NB, Hudspith BN, et al,. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 31-9.
31. Rigsbee L, Agans R, Shankar V, et al,. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2012; 107: 1740-51.
32. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al,. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-801.
33. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M,. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci 2012; 57: 1321-9.
34. Lin HC, Pimentel M,. Bacterial concepts in irritable bowel syndrome. Rev Gastroenterol Disord 2005; 5 (Suppl. 3): S3-9.
35. Pimentel M, Chow EJ, Lin HC,. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-6.
36. Bratten JR, Spanier J, Jones MP,. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008; 103: 958-63.
37. Yu D, Cheeseman F, Vanner S,. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60: 334-40.
38. Thabane M, Kottachchi DT, Marshall JK,. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-44.
39. Whelan K, Quigley EM,. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29: 184-9.
40. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P,. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15.
41. McFarland LV, Dublin S,. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-61.
42. Moayyedi P, Ford AC, Talley NJ, et al,. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32.
43. Cui S, Hu Y,. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med 2012; 5: 238-44.
44. Ringel Y, Ringel-Kulka T,. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2011; 45 (Suppl.): S145-8.
45. Whelan K,. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14: 581-7.
46. Maccaferri S, Candela M, Turroni S, et al,. IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation. Gut Microbes 2012; 3: 406-13.
47. Quigley EM, Flourie B,. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007; 19: 166-72.
48. Kumar A, Rinwa P, Sharma N,. Irritable bowel syndrome: a review. J Phys Pharm Adv 2012; 2: 97-108.
49. O'Mahony L, McCarthy J, Kelly P, et al,. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
50. Tillisch K, Labus J, Kilpatrick L, et al,. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394-401.
51. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR,. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-18.
52. Andriulli A, Neri M, Loguercio C, et al,. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 2008; 42 (Suppl. 3 Pt 2): S218-23.
53. Dughera L, Elia C, Navino M, Cisaro F,. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed 2007; 78: 111-6.
54. Pimentel M, Chow EJ, Lin HC,. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9.
55. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y,. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006; 51: 1297-301.
56. Pimentel M, Lembo A, Chey WD, et al,. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
57. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I,. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33.
58. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y,. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-63.
59. Menees SB, Maneerattannaporn M, Kim HM, Chey WD,. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35.
60. Meyrat P, Safroneeva E, Schoepfer AM,. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36: 1084-93.
61. Pimentel M, Morales W, Chua K, et al,. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011; 56: 2067-72.
62. Weinstock LB,. Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome. Dig Dis Sci 2011; 56: 3389-90.
63. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M,. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53: 169-74.
64. Jiang ZD, Ke S, DuPont HL,. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010; 35: 278-81.
65. Brown EL, Xue Q, Jiang ZD, Xu Y, DuPont HL,. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010; 54: 388-96.
66. DuPont HL,. Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother 2011; 12: 293-302.
67. Xu D, Gao J, Gillilland M III, et al,. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014; 146: 484-96.
68. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ,. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61: 1284-90.
69. Mayer EA,. The neurobiology of stress and gastrointestinal disease. Gut 2000; 47: 861-9.
70. Mayer EA, Tillisch K,. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381-96.
71. Drossman DA,. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998; 60: 258-67.
72. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM,. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-30.
73. Rhee SH, Pothoulakis C, Mayer EA,. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306-14.
74. Forsythe P, Kunze WA,. Voices from within: gut microbes and the CNS. Cell Mol Life Sci 2013; 70: 55-69.
75. Collins SM, Surette M, Bercik P,. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735-42.
76. Bajaj JS, Ridlon JM, Hylemon PB, et al,. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168-75.
77. Bercik P, Denou E, Collins J, et al,. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 609.
78. Dupont AW, DuPont HL,. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011; 8: 523-31.
79. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG,. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-52.
80. Chadwick VS, Chen W, Shu D, et al,. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
81. Crouzet L, Gaultier E, Del'Homme C, et al,. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013; 25: e272-82.
82. Verdú EF, Bercik P, Verma-Gandhu M, et al,. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-90.
83. Johnson AC, Greenwood-Van MB, McRorie J,. Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci 2011; 56: 3179-86.
84. Eutamene H, Lamine F, Chabo C, et al,. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137: 1901-7.
85. Azpiroz F, Bouin M, Camilleri M, et al,. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007; 19: 62-88.
86. Husebye E, Hellstrom PM, Sundler F, Chen J, Midtvedt T,. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G368-80.
87. Tattoli I, Petitta C, Scirocco A, Ammoscato F, Cicenia A, Severi C,. Microbiota, innate immune system, and gastrointestinal muscle: ongoing studies. J Clin Gastroenterol 2012; 46 (Suppl.): S6-11.
88. Efskind PS, Bernklev T, Vatn MH,. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-8.
89. Cremonini F, Talley NJ,. Treatments targeting putative mechanisms in irritable bowel syndrome. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 82-8.
90. Dahlqvist G, Piessevaux H,. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Acta Gastroenterol Belg 2011; 74: 375-80.
91. Camilleri M,. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2013; 14: 1151-60.
92. Quigley EM,. Do patients with functional gastrointestinal disorders have an altered gut flora? Therap Adv Gastroenterol 2009; 2: 23-30.